CD276 and non-small cell lung carcinoma: B7-H3 blockade using monoclonal antibodies and antibody-drug conjugates incited antitumor activity in B7-H3 positive tumors in vivo, and the combination of anti-PDL1 with B7-H3 has emerged as a promising strategy for the treatment of B7-H3-expressing non-small cell lung cancer (55–57).